MDLinx Neuro Brief

New study discredits a decade of research, a first-of-its-kind MS therapy, and a new Alzheimer’s risk factor

This week, researchers added tons of new options to the neurologist’s diagnostic and preventive toolkit, including a simple algorithm to predict Parkinson’s disease risk, more robust data on common risk factors, and new biomarkers. But that’s not all. This week, we highlight several new treatments you’ll want to try (including the first self-administered B-cell therapy…

Migraines linked to dangerous neurodegenerative disease, a diet for your brain, and a new risk factor for a common neurological condition

There’s a lot we still don’t know about COVID-19, but as time goes on the picture becomes a bit clearer. Unfortunately, it’s a pretty grim one. The virus has killed more than 775,000 people worldwide, damaged economies, and even those who survive tell stories of serious downstream difficulties, including some that affect cognition. In this…

CBD vs brain cancer, plus new studies show impact of sex and hormones on dementia

Good and bad news about dementia abounds this week, as MDLinx covers the incredible worldwide reductions in the disease (good news) that disproportionately benefit certain people (bad news), as well as risk factors for the disease we can all control (good news) and some we can’t (there’s that bad news again). Beyond dementia, we highlight…

Game-changing strategies detect Alzheimer’s extremely early, common condition found to be leading cause of dementia deaths, and more

This week we’ve got lots of good news (and a little bad) about Alzheimer’s disease—from incredible advancements in assessing risk factors (up to 50 years before onset) to the potential for a faster, cheaper, more accessible diagnosis, and even new ways a leukemia drug might make a big difference for patients suffering from the all-too-common…

×